<DOC>
	<DOC>NCT01299142</DOC>
	<brief_summary>The purpose of this study is to determine the safety and tolerability of the anti-TSG101 human monoclonal antibody (FGI-101-1A6)when administered intravenously to healthy volunteers.</brief_summary>
	<brief_title>Safety and Pharmacokinetics Study of Human Monoclonal Antibody (FGI-101-1A6)</brief_title>
	<detailed_description>Primary - - To compare the safety profile of a single intravenous administration of FGI-101-1A6 as compared with Placebo Secondary - To evaluate the pharmacokinetics (PK) of a singel intravenous administration of FGI-101-1A6 - To evaluate the immunogenicity of FGI-101-1A6</detailed_description>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Healthy volunteers ages 1845 Normal laboratory (blood tests) results Prior immunization with liveattenuated vaccines</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Influenza</keyword>
	<keyword>antibodies</keyword>
	<keyword>monoclonal</keyword>
	<keyword>virus</keyword>
</DOC>